Literature DB >> 21907545

Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats.

Katelyn V Trecartin1, David J Bucci.   

Abstract

Kynurenic acid (KYNA) is a tryptophan metabolite that is present at high concentrations in the brains of persons with schizophrenia. This study tested the hypothesis that treatment with L-kynurenine (L-KYN), which increases KYNA concentration, would produce deficits in social behavior similar to those associated with schizophrenia. Rats treated with L-KYN throughout adolescence exhibited decreased social interaction when tested drug-free as adults. In contrast, neither acute nor chronic treatment during adulthood affected social behavior. These findings demonstrate that increases in KYNA concentration produce deficits in social behavior and that the adolescent brain is particularly susceptible to the effects of high KYNA concentration.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907545      PMCID: PMC3225639          DOI: 10.1016/j.schres.2011.08.014

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  26 in total

Review 1.  The alpha7 nicotinic acetylcholine receptor in neuronal plasticity.

Authors:  R S Broide; F M Leslie
Journal:  Mol Neurobiol       Date:  1999-08       Impact factor: 5.590

2.  Effects of novelty on behavior in the adolescent and adult rat.

Authors:  Kirstie H Stansfield; Cheryl L Kirstein
Journal:  Dev Psychobiol       Date:  2006-01       Impact factor: 3.038

3.  Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.

Authors:  S Erhardt; K Blennow; C Nordin; E Skogh; L H Lindström; G Engberg
Journal:  Neurosci Lett       Date:  2001-11-02       Impact factor: 3.046

Review 4.  Why does schizophrenia develop at late adolescence?

Authors:  C Harrop; P Trower
Journal:  Clin Psychol Rev       Date:  2001-03

5.  Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat.

Authors:  Paul D Shepard; Brian Joy; Lucy Clerkin; Robert Schwarcz
Journal:  Neuropsychopharmacology       Date:  2003-04-16       Impact factor: 7.853

6.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 7.  A review of 25 years of the social interaction test.

Authors:  Sandra E File; Pallab Seth
Journal:  Eur J Pharmacol       Date:  2003-02-28       Impact factor: 4.432

8.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

9.  Nicotine enhances contextual fear conditioning in C57BL/6J mice at 1 and 7 days post-training.

Authors:  Thomas J Gould; J Stephen Higgins
Journal:  Neurobiol Learn Mem       Date:  2003-09       Impact factor: 2.877

10.  Dorsal hippocampus and classical fear conditioning to tone and context in rats: effects of local NMDA-receptor blockade and stimulation.

Authors:  Tobias Bast; Wei-Ning Zhang; Joram Feldon
Journal:  Hippocampus       Date:  2003       Impact factor: 3.899

View more
  16 in total

1.  Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice.

Authors:  M K Larsson; A Faka; M Bhat; S Imbeault; M Goiny; F Orhan; A Oliveros; S Ståhl; X C Liu; D S Choi; K Sandberg; G Engberg; L Schwieler; S Erhardt
Journal:  Neurochem Res       Date:  2016-05-10       Impact factor: 3.996

2.  Cholinergic systems are essential for late-stage maturation and refinement of motor cortical circuits.

Authors:  Dhakshin S Ramanathan; James M Conner; Arjun A Anilkumar; Mark H Tuszynski
Journal:  J Neurophysiol       Date:  2014-12-10       Impact factor: 2.714

3.  Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood.

Authors:  Britta Hahn; Carolyn H Reneski; Ana Pocivavsek; Robert Schwarcz
Journal:  Psychopharmacology (Berl)       Date:  2017-11-11       Impact factor: 4.530

4.  Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.

Authors:  Maximilian Tufvesson-Alm; Lilly Schwieler; Robert Schwarcz; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

5.  Enzymatic transamination of D-kynurenine generates kynurenic acid in rat and human brain.

Authors:  Veronica Pérez-de la Cruz; Laura Amori; Korrapati V Sathyasaikumar; Xiao-Dan Wang; Francesca M Notarangelo; Hui-Qiu Wu; Robert Schwarcz
Journal:  J Neurochem       Date:  2012-02-02       Impact factor: 5.372

6.  The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.

Authors:  Hannah F Iaccarino; Raymond F Suckow; Shan Xie; David J Bucci
Journal:  Schizophr Res       Date:  2013-09-30       Impact factor: 4.939

Review 7.  Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.

Authors:  Francesca M Notarangelo; Ana Pocivavsek
Journal:  Neuropharmacology       Date:  2016-03-02       Impact factor: 5.250

8.  Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine.

Authors:  K S Alexander; A Pocivavsek; H-Q Wu; M L Pershing; R Schwarcz; J P Bruno
Journal:  Neuroscience       Date:  2013-02-06       Impact factor: 3.590

9.  Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats.

Authors:  Ana Pocivavsek; Marian A R Thomas; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Psychopharmacology (Berl)       Date:  2014-03-04       Impact factor: 4.530

Review 10.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.